PDEs are an attractive pharmaceutical target for COPD and asthma treatment. Dual PDE4/3 inhibitor (RPL554) demonstrated anti-inflammatory and airway-modulatory effects in phase I clinical trials. Further clinical studies to explore the real pharmaceutical target of RPL554 were recommended. The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.